How long should someone with covid-19 wait to get vaccinated?
25:58
(CNN) - The
United States could have an estimated 300 million overdose of covid-19 vaccines by the end of July, according to a report from Duke University.
The researchers used data on the US government's advance purchase commitments to pharmaceutical giants to arrive at the estimate.
The country has vaccine commitments with Pfizer, Moderna, Johnson & Johnson, AstraZeneca, and Novavax.
The AstraZeneca and Novavax vaccines have not yet received emergency use authorization in the US, according to the Food and Drug Administration (FDA).
The report's authors also reviewed vaccine production schedules and used data from the United States Census to estimate demand.
advertising
His estimate shows that the nation retains enough doses for the majority of the country's minors.
Rich countries vaccinate 1 person per second, while most poorer nations have not given a single vaccine
They denounce that rich countries hoard vaccines 1:12
The excess of vaccines in the US
The researchers also assume that 75% of the US population will receive a two-dose vaccine and 25% will receive a one-shot Johnson & Johnson vaccine.
Given the recent hiatus that will limit Johnson & Johnson vaccine use in the United States, their projections may not be entirely accurate.
Regardless, the United States and other wealthier countries should expect to have a surplus of vaccines in the future, the authors write.
Currently, 10 countries representing less than half of the world's population have used three-quarters of the doses of the covid-19 vaccine, but many poorer countries still do not have a supply.
WHO: 'Much of the world could be left behind' as rich countries try to 'skip the line' on vaccines
“The richest nations in the world have secured much of the short-term supply.
At the current rate of vaccination, 92 of the world's poorest countries will not vaccinate 60% of their population until 2023 or later, ”wrote Dr. Krishna Udayakumar, director of the Duke Center for Global Health Innovation. and Dr. Mark McClellan, director of the Duke-Margolis Center for Health Policy.
"Now is the time to advance an effective plan to distribute additional excess doses as they become available."
The authors say the United States should invest more to strengthen the Covax program's vaccine scheme and make excess doses available to other nations.
He also writes that the United States must support other nations so that they can produce vaccines on their own.
Covid-19 Coronavirus Vaccine